 NEW YORK, Sept. 01, 2022 GLOBE NEWSWIRE -- Cellectis the Company Euronext Growth: ALCLS - NASDAQ: CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management plans to participate in four upcoming investor conferences. 